GHK-Cu + Epithalon

Where the name "GHK-Cu + Epithalon" comes from

"GHK-Cu + Epithalon" is not a name from the literature. It is community and market usage — a two-item component list that circulates as a longevity combination — and Peptide Health Lab neither coined it nor endorses it. This page exists because the component list is what people search for.

Where the name came from is not documented. A PubMed search on 1 September 2026 for (epithalon OR epitalon) AND (GHK-Cu OR GHK) AND (stack OR protocol OR regimen OR blend) returned one record, a 2026 narrative review of peptides in gerontology that discusses the two compounds in different sections and proposes no combination of them.^[2] Rather than invent a provenance, this page reports what the searches returned.

Dosing and protocol ranges are not on this page; they are on each component's own page, in the population and route the study used.

What's in it and why people combine them

GHK-Cu is the component with the longer paper trail, and almost all of it is cells. The one register in which it has been measured in a living animal outside the skin is muscle: in mice with cigarette-smoke-induced skeletal muscle dysfunction, the copper complex reduced muscle mass loss and rescued muscle weakness through a sirtuin 1-dependent pathway, in a study that also found lower plasma GHK in patients with chronic obstructive pulmonary disease than in age-paired healthy subjects.^[8] That is a mouse result about smoke-injured muscle, not an aging outcome — and a 2025 review of the topical GHK literature, the register the compound is actually famous in, describes a surprising absence of clinical studies of GHK-Cu and its derivatives.^[9]

Epithalon carries a much older reputation that belongs to something else. Epithalon, also written epitalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly. Epithalamin is a polypeptide complex extracted from the pineal gland of cattle. They are different substances, and that is not this page's characterization: the US Food and Drug Administration states in the briefing document prepared for its Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 that it considers epitalon and epithalamin different substances, describes epithalamin as a polypeptide complex extracted from the pineal gland, and notes that epithalamin is not listed as a synonym for epitalon in FDA's Global Substance Registration System. That document was retrieved on 1 September 2026.

The bridge between the two names is an analytical claim: the same St Petersburg group that publishes most of this literature reported identifying the AEDG sequence inside the pineal extract.^[3] Finding a sequence inside a complex mixture is a chemistry result. It is not evidence that giving the isolated tetrapeptide reproduces what the mixture did.

The reason people put these two together is a story about layers: matrix and copper signalling from one, telomere and circadian signalling from the other. That is an account assembled by a reader. It is not a result.

What the evidence says about the combination

A PubMed search on 1 September 2026 for (GHK-Cu OR GHK OR "copper tripeptide" OR "glycyl-histidyl-lysine" OR "copper peptide") AND (epithalon OR epitalon OR "Ala-Glu-Asp-Gly" OR AEDG) returned two records; the narrower GHK-Cu AND epithalon returned one; "copper peptide" AND epitalon returned zero; "glycyl-histidyl-lysine" AND "Ala-Glu-Asp-Gly" returned zero; and (GHK-Cu OR "copper tripeptide") AND (pineal OR melatonin) returned zero. A search of ClinicalTrials.gov on the same date for the two compounds as a single intervention returned zero registered studies.

The two records are both 2026 narrative reviews. One catalogues therapeutic peptides in orthopaedics and names GHK-Cu among wound-healing peptides in one sentence and epithalon among agents said to target circadian and mitochondrial regulators in the next, concluding in its own abstract that there is a current lack of clinical trials.^[1] The other reviews peptides in gerontology, files GHK-Cu under dermal regeneration and epitalon under telomere biology, and lists combination therapy effects among the significant knowledge gaps it identifies.^[2] A review naming two compounds in adjacent sentences is a co-mention, not combination data.

There is one published test of whether GHK-Cu adds anything to a second agent, and the second agent is not on this page. Human dermal fibroblasts and an ex-vivo skin model were treated with a series of GHK-Cu and hyaluronic acid combinations, and the best-performing one raised collagen IV 25.4-fold in the cell test and 2.03-fold in the ex-vivo test.^[7] The gap between those two numbers is the more useful half of the result, and the partner molecule is hyaluronic acid. Nothing about that experiment reaches a tetrapeptide.

There is one human co-administration study anywhere near this space, and it used neither of these two molecules. Two institutes assessed thymic and pineal peptide preparations in 266 elderly people over six to eight years and reported mortality falling 1.6 to 1.8-fold in the pineal-preparation group and 4.1 times in a subgroup given both preparations annually for six years; PubMed types the record Clinical Trial and Randomized Controlled Trial, while the abstract describes a clinical assessment against a control and never states how anyone was allocated.^[5] The substances were Thymalin and Epithalamin — two extracts. That study is the contrast case for this page, not its support: it is what a combination result looks like when someone administers a combination, and the combination was of different substances.

The combination claim here is graded anecdotal because the combination has never been administered to anything, in any species, for any endpoint the searches above could find. Evidence about GHK-Cu and evidence about epithalon do not add up to evidence about the two of them together.

Where the evidence is weak

The randomized human evidence for "epithalon" is not evidence for epithalon. On 1 September 2026, a PubMed search for (epithalon OR epitalon) AND "randomized controlled trial"[pt] returned zero records. The identical query run against (epithalamin OR epithalamine) returned six. That is the whole identity trap in two numbers from the same field on the same day: the randomized-trial-typed literature belongs to the extract. The single record PubMed types as any kind of clinical trial of the tetrapeptide itself is a 2002 retinitis pigmentosa report typed Clinical Trial and Controlled Clinical Trial, with no control group, no blinding and no participant count in its abstract.^[4]

The literature is concentrated in one group, measured rather than asserted. On 1 September 2026, (epithalon OR epitalon) returned 142 PubMed records; adding Khavinson[au] returned 90, or 63%; adding the extended St Petersburg author set — Khavinson, Anisimov, Korkushko, Morozov, Ryzhak, Trofimova, Kvetnoi and Linkova — returned 101, or 71%. Restricted to humans[MeSH] the corpus is 41 records, of which 23, or 56%, carry Khavinson. Of the six randomized-trial-typed epithalamin records, five carry Khavinson or Ryzhak as an author; the sixth is a 1999 Russian-language cervical cancer treatment report. No independent-group framing is available for the human material here, and the analytical bridge between the extract and the tetrapeptide comes from the same group as well.^[3]

The one genuinely independent replication is two-sided. A group at Brunel University London and the Royal Brompton Hospital, carrying none of those authors, reproduced dose-dependent telomere lengthening with the tetrapeptide in normal cells — and in the same experiment found significant telomere lengthening in breast cancer lines through alternative lengthening of telomeres, which they report as specific to the cancer cells.^[6] Lengthening telomeres in cancer cells is a reason for caution, not a reassurance. That paper's PubMed record also carries a published erratum in the same journal, indexed in November 2025 and read from PubMed on 1 September 2026, so the corrected version is the one to read.

The route in the regulatory record is not the route the name implies. FDA's list of bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, updated 14 May 2026 and retrieved on 1 September 2026, carries GHK-Cu in Category 1, substances under evaluation, in the explicit form "GHK-Cu (except for injectable routes of administration)" — the nominations having been withdrawn in April 2026 and one nominator having clarified in May 2026 that it wished to retain the nomination for non-injectable routes only. Epitalon appears nowhere in that document; its own nominations were withdrawn, and FDA's July 2026 briefing document states that neither epitalon free base nor epitalon acetate is a component of an FDA-approved drug and that no United States Pharmacopeia or National Formulary monograph exists for either. Both facts were read from the documents themselves, not from any paper. ClinicalTrials.gov, searched on the same date, returned three registered studies naming GHK-Cu as an intervention — including an industry-sponsored phase 2 trial of a topical gel against a vehicle control, recruiting with no results posted — and zero naming epithalon or epitalon under any spelling.

Questions to bring to a provider

The useful version of this conversation is not "is this combination worth trying." It is "what am I actually trying to change, and what has been measured in a person."

• Which of the two compounds is the reason for the interest? The searches recorded above returned no study that administered them together, and the 2026 orthopaedic review that names both files them under different mechanisms entirely — GHK-Cu among wound-healing peptides, epithalon among agents said to target circadian and mitochondrial regulators — while concluding in its own abstract that there is a current lack of clinical trials.^[1]
• If the appeal is the mortality or geroprotection result, does it change anything to know that the study administered two pineal and thymic extracts rather than either molecule here?^[5]
• Given a personal or family history of malignancy, how should a result showing telomere lengthening in breast cancer cell lines be weighed against a result showing it in normal cells?^[6]
• What would count as an objective change, measured at a fixed interval, rather than a subjective one? In the register GHK-Cu is best known in, a 2025 review reports in its own results that there is a surprising absence of clinical studies of the copper complex and its palmitoylated derivative in the anti-wrinkle products they are sold in.^[9]
• What interactions with current prescribed medication would a clinician want to consider before an unapproved compound is part of the conversation?

Anti-doping status

Neither component of this combination is named on the World Anti-Doping Agency Prohibited List in force for 2026. Searching that document, the 2026 Monitoring Program and the 2026 Explanatory Note on 1 September 2026 for the strings GHK, copper, glycyl, tripeptide, epithalon, epitalon, pineal and AEDG returned zero occurrences of any of them in any of the three documents. All three were read as published, not as summarized by any paper.

Absence from the List is not permission. Section S0 reaches any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use; the 2026 text gives BPC-157 and three other examples of what it calls a class covering many different substances, which makes S0 a criterion and not a closed catalogue. The question S0 asks about these two compounds is therefore an approval question, answered against each compound's own regulatory record rather than by habit.

That record, as set out in the FDA compounding documents described above, is a nomination record for both compounds, and a nomination is not an approval. No approval for human therapeutic use was found for either compound at any regulator searched on 1 September 2026, so the ordinary reading of S0's criterion applies to both — and an athlete subject to testing should treat an unapproved compound as a question for their national anti-doping organization rather than as a settled absence.

Every status above was read from the anti-doping and regulatory documents themselves rather than from the research literature. The distinction is visible in this page's own sources: the 2026 gerontology review describes searching regulatory databases as part of its method, and still correctly limits its conclusion to saying that investigational peptides require validation through well-designed clinical trials.^[2] A review can report what has been published; only a regulator's own document establishes what a regulator has done. The List is reissued annually and its sections renumber, so an athlete subject to testing should confirm the current year's list rather than this page.